Deltacron, a new variant of corona virus has knocked in India and 568 cases are under investigation in 7 states including Maharashtra-Delhi. In the midst of all this, there is a big and relief news and the emergency use of Novavax Covid-19 Vaccine has been approved. Let us tell you that Novavax has announced the approval of emergency use of its Covid-19 vaccine for children aged 12-18 years in India. Yes, on the other hand, according to an official statement issued by Novavax, the vaccine is also known as NVX-CoV2373. Yes and in India this vaccine has been manufactured by the Serum Institute of India based in Pune and has been launched under the brand Covovax.
In fact, this is the first protein-based vaccine, which has been authorized for use in this age group in India. Let us tell you all that the Drug Controller General of India (DCGI) has issued a State of Emergency of Covovax Covovax for active immunization to prevent the COVID-19 infection caused by SARS-CoV-2 in people 12 years of age and above. restricted use is permitted. Let us also inform you that the DCGI on December 28 approved the emergency use of 'Kovovax' for adults 18 years of age and older.
However, in early December, the World Health Organization (WHO) approved the emergency use of Kovovax. Let us tell you that in the meantime Stanley C Erck, President and CEO of Novavax, said, 'We are proud to have received the first approval of this vaccine for children. Our data suggests that the efficacy and safety of this vaccine will provide an alternative protein-based vaccine option for individuals 12 years of age and above in India. Let us tell you that Novavax is a protein subunit vaccine and it is completely different from other vaccines. The protein subunit is an important part of vaccines that they protect against.
Modi govt's big decision on prisoners lodged in jail
Covid Updates: India reports 1,778 fresh cases in last 24 hours
